HCW Biologics Inc

NASDAQ HCWB

Data sourced from

and

Download Data

HCW Biologics Inc Sales to Operating Cash Flow Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 58.32%

HCW Biologics Inc Sales to Operating Cash Flow Ratio 1 year YoY Change (%) is 58.32% for the Trailing 12 Months (TTM) ending March 31, 2024, a 138.64% change year over year. Sales to operating cash flow ratio measures the revenue generated by a company relative to its operating cash flow. It is calculated by dividing the revenue by the operating cash flow. This ratio provides insights into the efficiency of revenue generation compared to the company's operating cash flow. A higher sales to operating cash flow ratio suggests better revenue generation efficiency. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

HCW Biologics Inc Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending December 31, 2022 was -0.82, a 0.00% change year over year.
HCW Biologics Inc Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending December 31, 2021 was 0.00, a 100.00% change year over year.
HCW Biologics Inc Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending December 31, 2020 was -0.39.

NASDAQ: HCWB

HCW Biologics Inc

CEO	Dr. Hing C. Wong Ph.D.
IPO Date	July 20, 2021
Location	United States
Headquarters	2929 North Commerce Parkway, Miramar, FL, United States, 33025
Employees	45
Sector	Healthcare
Industry	Biotechnology

Description

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Key trends